Association Between Serum Cytotoxic T Lymphocyte Antigen (CTLA)-4 Level and Disease Progression in Patients With Chronic Hepatitis B.
CTLA-4
chronic hepatitis B
hepatocellular carcinoma
liver cirrhosis
Journal
Medical archives (Sarajevo, Bosnia and Herzegovina)
ISSN: 1986-5961
Titre abrégé: Med Arch
Pays: Bosnia and Herzegovina
ID NLM: 101635337
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
06
12
2022
accepted:
08
03
2023
medline:
5
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Immune impairment, marked by increased expression of cytotoxic T lymphocyte antigen (CTLA)-4, promotes the disease progression of chronic hepatitis B. This study aimed to determine the association between serum CTLA-4 level and disease progression in patients with chronic hepatitis B. A cross-sectional study was conducted at Haji Adam Malik General Hospital Medan, Indonesia between October 2021 to September 2022. A total of 150 participants were enrolled. Patients aged 18 years or older with evidence of chronic hepatitis B, HBV-related liver cirrhosis, and HBV-related hepatocellular carcinoma (HCC) were enrolled. Exclusion criteria were history of chronic hepatotoxic drug consumption, underlying liver abnormalities other than HBV infection, and liver injury due to metastasized malignancy from other sites. Serum CTLA-4 level was determined from serum using human CTLA-4 enzyme linked immunosorbent assay kit. Most participants were males and aged between 40 and 60 years. Serum CTLA-4 level was positively associated with chronic hepatitis B progression (P<0.001). Serum CTLA-4 level was negatively correlated with serum platelet (P<0.001) and albumin levels (P<0.001) but positively correlated with serum ALT (P=0.045) and total bilirubin levels (P<0.001). Serum CTLA-4 level is associated with disease progression in patients with chronic hepatitis B.
Identifiants
pubmed: 37260808
doi: 10.5455/medarh.2023.77.142-145
pmc: PMC10227835
doi:
Substances chimiques
CTLA-4 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-145Informations de copyright
© 2023 Darmadi Darmadi, Dharma Lindarto, Jelita Siregar, Tri Widyawati, Muhammad Rusda, Mustafa Mahmud Amin, Fauzi Yusuf, Putri Chairani Eyanoer, Masrul Lubis, Imelda Rey.
Déclaration de conflit d'intérêts
authors declare that there are no conflicts of interest.
Références
Chronic Dis Transl Med. 2016 Nov 09;2(2):67-80
pubmed: 29063027
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671581
Int J Mol Med. 2018 Aug;42(2):703-712
pubmed: 29786112
World J Gastroenterol. 2009 Aug 28;15(32):4028-36
pubmed: 19705499
ISRN Gastroenterol. 2013;2013:935295
pubmed: 23401786
World J Gastroenterol. 2018 May 7;24(17):1839-1858
pubmed: 29740200
World J Gastroenterol. 2015 Oct 14;21(38):10721-31
pubmed: 26478664
Int Immunopharmacol. 2020 Mar 9;82:106377
pubmed: 32163858
Int J Mol Sci. 2017 Jul 13;18(7):
pubmed: 28703774
Int J Clin Exp Pathol. 2015 Nov 01;8(11):15118-22
pubmed: 26823853
World J Gastroenterol. 2015 Oct 14;21(38):10714-20
pubmed: 26478663
Auto Immun Highlights. 2010 Nov 04;1(2):73-81
pubmed: 26000110
World J Gastroenterol. 2019 Jul 21;25(27):3527-3537
pubmed: 31367154
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307